Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
Data from two studies in obstructive sleep apnea suggest drug may hold its own against approved generics, analysts say.
Unlike Amgen's FOURIER study of Repatha, which disappointed investors with a lower magnitude of benefit than expected, Esperion's outcomes trial of bempedoic acid will be done in patients with higher baseline LDL and will be much longer.
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.